1
|
Siroski PA, Russi NB, Ortega HH, Formentini EA. In vitro evaluation of synergistic activity between ciprofloxacin and broad snouted caiman serum against Escherichia coli. Res Vet Sci 2014; 98:98-105. [PMID: 25468795 DOI: 10.1016/j.rvsc.2014.11.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2014] [Revised: 09/04/2014] [Accepted: 11/06/2014] [Indexed: 11/15/2022]
Abstract
The in vitro synergistic activity between ciprofloxacin and serum of broad snouted caiman on Escherichia coli was studied. The estimated MIC value of ciprofloxacin was 0.0188 µg/ml, and two assays of kill curve during 5 hours were performed: the first one in a standard culture medium and the second one in the presence of caiman serum. Different concentrations of ciprofloxacin were tested. Ciprofloxacin showed higher values of bacterial elimination rate in the presence of caiman serum in all concentrations tested. The combined activity of sub-inhibitory concentrations of ciprofloxacin and the humoral immune factors present in caiman serum determined an increase in the bacterial elimination observed in this assay. We suggest that the antibacterial activity of complement and natural antibodies present in caiman serum, which can bind to both Gram-negative and Gram-positive bacteria and acting through the classical complement pathway, can inhibit bacterial growth of Escherichia coli by lysis.
Collapse
Affiliation(s)
- P A Siroski
- ICIVET-CONICET-Facultad de Ciencias Veterinarias, Universidad Nacional del Litoral, R.P. Kreder 2805, CP S3080HOF Esperanza, Santa Fe, Argentina; Laboratorio de Zoología Aplicada: Anexo Vertebrados (FHUC-UNL/MASPyMA) Departamento de ciencias Naturales, Facultad de Humanidades y Ciencias, Universidad Nacional del Litoral, Ciudad Universitaria -Paraje El Pozo, CP S3000 Santa Fe, Argentina.
| | - N B Russi
- Laboratorio de Bacteriología del Hospital de Salud Animal-Facultad de Ciencias Veterinarias, Universidad Nacional del Litoral, R.P. Kreder 2805, CP S3080HOF Esperanza, Santa Fe, Argentina
| | - H H Ortega
- ICIVET-CONICET-Facultad de Ciencias Veterinarias, Universidad Nacional del Litoral, R.P. Kreder 2805, CP S3080HOF Esperanza, Santa Fe, Argentina
| | - E A Formentini
- Cátedra de Farmacología-Facultad de Ciencias Veterinarias, Universidad Nacional del Litoral, R.P. Kreder 2805, CP S3080HOF Esperanza, Santa Fe, Argentina
| |
Collapse
|
2
|
Beri S, Sidhu PK, Kaur G, Chandra M, Rampal S. Comparative mutant prevention concentration and antibacterial activity of fluoroquinolones against Escherichia coli in diarrheic buffalo calves. J Chemother 2014; 27:312-6. [PMID: 24575977 DOI: 10.1179/1973947814y.0000000173] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Owing to emerging threat of antimicrobial resistance, mutant prevention concentration (MPC) is considered as an important parameter to evaluate the antimicrobials for their capacity to restrict/allow the emergence of resistant mutants. Therefore, MPCs of ciprofloxacin, enrofloxacin, levofloxacin, moxifloxacin, and norfloxacin were determined against Escherichia coli isolates of diarrheic buffalo calves. The minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were also established. The MICs of ciprofloxacin, enrofloxacin, levofloxacin, moxifloxacin and norfloxacin were 0·009, 0·022, 0·024, 0·028, and 0·036 μg/ml, respectively. The MBCs obtained were very close to the MICs of respective drugs that suggested a bactericidal mode of action of antimicrobials. The MPCs (μg/ml) of ciprofloxacin (4·2×MIC), moxifloxacin (4·8×MIC), and norfloxacin (5·1×MIC) were approximately equal but slightly lower than enrofloxacin (7·6×MIC) and levofloxacin (8·5×MIC) against clinical isolates of E. coli. The MPC data suggested that enrofloxacin has the potential for restricting the selection of E. coli mutants during treatment at appropriate dosing.
Collapse
|
3
|
Cengiz M, Sahinturk P, Sonal S, Buyukcangaz E, Sen A, Arslan E. In vitro bactericidal activity of enrofloxacin against gyrA mutant and qnr-containing Escherichia coli isolates from animals. Vet Rec 2013; 172:474. [PMID: 23605176 DOI: 10.1136/vr.101331] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
The objective of this work was to investigate the bactericidal activity of enrofloxacin against gyrA mutant and qnr-containing Escherichia coli isolates from animals. The minimum inhibitory concentrations (MICs) of gyrA mutant and qnr-containing E coli isolates ranged from 1 µg/ml to 32 µg/ml for enrofloxacin. Time-kill experiments were performed using selected E coli isolates. For the time-kill experiments, the colony counts were determined by plating each diluted sample onto plate count agar and an integrated pharmacokinetic/pharmacodynamics area measure (log ratio area) was applied to the colony-forming units (cfu) data. In general, enrofloxacin exhibited bactericidal activity against all the gyrA mutant E coli isolates at all concentrations greater than four times the MIC. However, the bactericidal activity of enrofloxacin for all the qnr-containing E coli isolates was less dependent on concentration. The results of the present study indicated that the genetic mechanism of resistance might account for the different bactericidal activities of enrofloxacin observed for the gyrA mutant and the qnr-containing E coli isolates. Therefore, in addition to MIC assays, genetic mechanism-based pharmacodynamic models should be used to provide accurate predictions of the effects of drugs on resistant bacteria.
Collapse
Affiliation(s)
- M Cengiz
- Laboratory of Molecular Pharmacology, Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Uludag University, Nilufer, Bursa 16059, Turkey.
| | | | | | | | | | | |
Collapse
|
4
|
Respaud R, Grayo S, Singlas E, Dubouch S, Le Monnier A, Lott MC. High-performance liquid chromatography assay for moxifloxacin in brain tissue and plasma: validation in a pharmacokinetic study in a murine model of cerebral listeriosis. JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY 2012; 2012:436349. [PMID: 22567560 PMCID: PMC3335337 DOI: 10.1155/2012/436349] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/21/2011] [Accepted: 12/29/2011] [Indexed: 05/03/2023]
Abstract
Moxifloxacin is a broad-spectrum antibacterial 8-methoxy-fluoroquinolone. In order to evaluate the pharmacokinetic properties of moxifloxacin in mouse plasma and brain tissue, we developed a high-performance liquid chromatography (HPLC) method. This study was based on single-drug delivery, intravenously dosed in a central listeriosis murine model. The method employed a reversed-phase Lichrospher RP-18 with a precolumn (250 × 4.6 mm) and a mobile phase composed of a mixture of acetonitrile, methanol, and citric buffer (pH = 3.5) with sodium dodecyl sulfate and tetrabutylammonium bromide. Fluorescence detection was performed at an excitation wavelength of 290 nm and an emission wavelength of 550 nm. The relative standard deviation of intra- and inter-day assays was <10%. This validated method led to a short retention time (8.0 min) for moxifloxacin. The standard curves were linear from 5-250 μg/L in plasma and from 0.1-2.5 μg/g of brain tissue. The limits of quantification were 5 μg/L in plasma and 0.1 μg/g in brain tissue. The method enabled the detection of systemic antimicrobial in plasma and in CNS in Listeria-infected mice. Injected moxifloxacin passed through the encephalic barrier within a 30 to 60 min after injection time frame. Moxifloxacin pharmacokinetics are modeled in an infected model compared to control mice.
Collapse
Affiliation(s)
- Renaud Respaud
- Laboratoire de Suivi Thérapeutique et de Contrôle des Médicaments, Service de Pharmacie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker-Enfants Malades, 75015 Paris, France
- *Renaud Respaud:
| | - Solene Grayo
- Laboratoire de Listeria, Centre National de Référence des Listeria and World Health Organization Collaborating Centre for Foodborne Listeriosis, Institut Pasteur, 75015 Paris, France
| | - Eric Singlas
- Laboratoire de Suivi Thérapeutique et de Contrôle des Médicaments, Service de Pharmacie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker-Enfants Malades, 75015 Paris, France
| | - Sophie Dubouch
- Laboratoire de Suivi Thérapeutique et de Contrôle des Médicaments, Service de Pharmacie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker-Enfants Malades, 75015 Paris, France
| | - Alban Le Monnier
- Laboratoire de Listeria, Centre National de Référence des Listeria and World Health Organization Collaborating Centre for Foodborne Listeriosis, Institut Pasteur, 75015 Paris, France
| | - Marie-Catherine Lott
- Laboratoire de Suivi Thérapeutique et de Contrôle des Médicaments, Service de Pharmacie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker-Enfants Malades, 75015 Paris, France
| |
Collapse
|
5
|
Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis. Antimicrob Agents Chemother 2008; 52:3210-5. [PMID: 18573932 DOI: 10.1128/aac.00177-08] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Listeriosis is a rare but life-threatening infection. A favorable outcome is greatly aided by early administration of antibiotics with rapid bactericidal activity against Listeria monocytogenes. Moxifloxacin, a new-generation fluoroquinolone with extended activity against gram-positive bacteria, has proved its effectiveness in vitro against intracellular reservoirs of bacteria. The efficacies of moxifloxacin and amoxicillin were compared in vivo by survival curve assays and by studying the kinetics of bacterial growth in blood and organs in a murine model of central nervous system (CNS) listeriosis. We combined pharmacokinetic and pharmacodynamic approaches to correlate the observed efficacy in vivo with plasma and tissue moxifloxacin concentrations. Death was significantly delayed for animals treated with a single dose of moxifloxacin compared to a single dose of amoxicillin. We observed rapid bacterial clearance from blood and organs of animals treated with moxifloxacin. The decrease in the bacterial counts in blood and brain correlated with plasma and cerebral concentrations of antibiotic. Moxifloxacin peaked in the brain at 1.92 +/- 0.32 microg/g 1 hour after intraperitoneal injection. This suggests that moxifloxacin rapidly crosses the blood-brain barrier and diffuses into the cerebral parenchyma. Moreover, no resistant strains were selected during in vivo experiments. Our results indicate that moxifloxacin combines useful pharmacokinetic properties and rapid bactericidal activity and that it may be a valuable alternative for the treatment of CNS listeriosis.
Collapse
|
6
|
Kays MB, Lisek CR, Denys GA. Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology. Int J Antimicrob Agents 2007; 29:289-94. [PMID: 17240118 DOI: 10.1016/j.ijantimicag.2006.09.024] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2006] [Revised: 09/20/2006] [Accepted: 09/21/2006] [Indexed: 11/16/2022]
Abstract
Broth microdilution MICs were determined for 14 antimicrobial agents against 296 clinical, non-duplicate isolates of Streptococcus pneumoniae collected at Methodist Hospital (Indianapolis, Indiana, USA) from January 2001 to December 2003. Isolates were categorized as susceptible, intermediate, or resistant using Clinical and Laboratory Standards Institute breakpoints. Time-kill studies were performed to evaluate the bactericidal activity of telithromycin at 1, 2, 4, and 8x MIC against 10 penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant (7 M-phenotype, 3 MLS(B)-phenotype) strains. Bactericidal activity was defined as a >/=3-log(10) reduction in CFU/mL. The prevalence of resistance was highest for the macrolides (32%), followed by penicillin (16.2%), clindamycin (10.8%), amoxicillin+/-clavulanate (4.4%), levofloxacin (3.0%), gatifloxacin and moxifloxacin (2.4%), ceftriaxone and cefotaxime (2.0%), and gemifloxacin (1.4%). None of the isolates tested were resistant to telithromycin. At 24h, telithromycin was bactericidal for 0/10, 2/10, 7/10, and 7/10 isolates at 1x MIC, 2x MIC, 4x MIC, and 8x MIC, respectively. At 4-8x MIC, telithromycin was bactericidal for 7/7 M-phenotype isolates and 0/3 MLS(B)-phenotype isolates. For the MLS(B)-phenotype isolates, colony counts were decreased by 1.3-2.1log(10) colony-forming units/mL after 24h at 8x MIC. Overall, telithromycin was highly active against 296 isolates of S. pneumoniae from our institution and demonstrated bactericidal activity at clinically achievable concentrations for 7 of 10 penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant S. pneumoniae. However, telithromycin was bacteriostatic for the MLS(B)-phenotype isolates.
Collapse
Affiliation(s)
- Michael B Kays
- Purdue University School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice, W7555 Myers Building, WHS, 1001 West Tenth Street, Indianapolis, IN 46202, USA.
| | | | | |
Collapse
|
7
|
Abstract
Moxifloxacin (Avelox) is a fluoroquinolone antibacterial with a methoxy group in the C-8 position and a bulky C-7 side chain. Moxifloxacin is approved for use in the treatment of acute exacerbations of chronic bronchitis (AECB), community-acquired pneumonia (CAP), acute bacterial sinusitis and uncomplicated skin and skin structure infections (approved indications may differ between countries). Moxifloxacin has a broad spectrum of antibacterial activity, including activity against penicillin-resistant Streptococcus pneumoniae. It achieves good tissue penetration and has a convenient once-daily administration schedule, as well as being available in both intravenous and oral formulations in some markets. Moxifloxacin has good efficacy in the treatment of patients with AECB, CAP, acute bacterial sinusitis and uncomplicated skin and skin structure infections, and is generally well tolerated. Thus, moxifloxacin is an important option in the treatment of bacterial infections.
Collapse
|
8
|
Johnson CN, Benjamin Jr WH, Moser SA, Hollingshead SK, Zheng X, Crain MJ, Nahm MH, Waites KB. Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America. J Clin Microbiol 2003; 41:2458-64. [PMID: 12791865 PMCID: PMC156496 DOI: 10.1128/jcm.41.6.2458-2464.2003] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We characterized 32 levofloxacin-nonsusceptible Streptococcus pneumoniae (LNSP) isolates obtained from a broad geographic region of North America over a 5-year period by using capsular serotypes, antimicrobial susceptibility profiles, BOX-PCR, multilocus sequence typing (MLST), and pulsed-field gel electrophoresis (PFGE). Sixteen international clones identified by the Pneumococcal Molecular Epidemiology Network also were included for comparison. Fifteen serotypes were represented, with serogroups 6, 9, 14, 19, and 23 accounting for 63% of isolates. Among isolates whose quinolone resistance-determining regions were sequenced, all contained gyrA and parC point mutations. Sixty-three percent were penicillin susceptible, and 84% were erythromycin susceptible. BOX-PCR analysis identified 39 different band patterns among 32 LNSP and 16 international clones and grouped 16 isolates, including 2 international clones, into seven unrelated groups of 2 to 4 isolates each. PFGE analysis identified 35 different band patterns among 32 LNSP and 16 international clones and grouped 21 isolates, including 3 international clones, into eight unrelated groups of 2 to 6 isolates each. MLST performed on 10 isolates identified five allelic profiles and separated 9 isolates into four groups of 2 to 3 isolates each. Overall, each typing method indicated that the LNSP were heterogeneous and that resistance to fluoroquinolones was not closely associated with a particular serotype or with coresistance to other antimicrobial classes and suggests that LNSP have likely arisen through independent mutational events as a result of selective pressure. However, seven LNSP were found to be related to three international clones by PFGE.
Collapse
Affiliation(s)
- Crystal N Johnson
- Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 35249, USA
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Critchley IA, Blosser-Middleton RS, Jones ME, Karlowsky JA, Karginova EA, Thornsberry C, Sahm DF. Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000. Int J Antimicrob Agents 2003; 20:100-7. [PMID: 12297358 DOI: 10.1016/s0924-8579(02)00125-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
During 1999-2000, 5015 isolates were collected from 13 countries and tested against levofloxacin. Overall, levofloxacin resistance minimum inhibitory concentration (MIC>or =8 mg/l) was found in 40 isolates (0.8%). The highest resistance rates were in Hong Kong (8.0%), China (3.3%) and Spain (1.6%). Levofloxacin retained an MIC(90) of 1 mg/l in all countries. Pulsed-field gel electrophoresis analysis of resistant isolates demonstrated the presence of clones in countries where levofloxacin resistance exceeded 1%, suggesting that the elevated resistance rates could result from resistant clones within participating hospitals. DNA-sequence analysis of the quinolone-resistance-determining regions of gyrA, gyrB, parC and parE genes showed that the most common mutations were in GyrA (Ser81Phe), ParC (Ser79Phe, Lys137Asn) and ParE (Ile460Val), accounting for 40% of the isolates tested. Levofloxacin-resistant isolates were generally non-susceptible to other fluoroquinolones tested. Future studies to characterise resistant isolates by other molecular methods may ensure that the appropriate counter-measures can be taken to control the spread of resistant isolates.
Collapse
Affiliation(s)
- Ian A Critchley
- Focus Technologies, Inc., 13665 Dulles Technology Drive, Herndon, VA 20171, USA.
| | | | | | | | | | | | | |
Collapse
|
10
|
Kays MB, Smith DW, Wack ME, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002; 22:395-9. [PMID: 11898897 DOI: 10.1592/phco.22.5.395.33185] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The frequency of fluoroquinolone-resistant Streptococcus pneumoniae has increased as fluoroquinolone administration for treatment of respiratory tract infections has increased. Levofloxacin treatment failed in a patient who had pneumococcal pneumonia and had received three previous courses of levofloxacin therapy. Susceptibility testing revealed high-level resistance to levofloxacin (minimum inhibitory concentration [MIC] > 32 microg/ml), and cross-resistance to moxifloxacin (MIC 4 microg/ml), trovafloxacin (6 microg/ml), and gatifloxacin (12 microg/ml). Sequencing of the quinolone-resistance determining region revealed a mutation of serine-81 to phenylalanine (Ser81-->Phe) in the gyrA region of DNA gyrase and a Ser79-->Phe mutation in the parC region of topoisomerase IV The patient was treated successfully with intravenous ceftriaxone followed by oral cefprozil. Clinicians must be aware of local resistance patterns and the potential for fluoroquinolone treatment failures in patients with infections caused by S. pneumoniae.
Collapse
Affiliation(s)
- Michael B Kays
- Department of Pharmacy Practice, Purdue University School of Pharmacy and Pharmacal Sciences, Indianapolis, IN 46202-2879, USA
| | | | | | | |
Collapse
|
11
|
Bhavnani SM, Ambrose PG, Jones RN. Pharmacodynamics in the evaluation of drug regimens. Ann Pharmacother 2002; 36:530-2. [PMID: 11895071 DOI: 10.1345/aph.1a419] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
We believe, especially in an era of increasing antimicrobial resistance, that the integration of PK/PD models and stochastic techniques provides a powerful new tool to clinicians, researchers, and regulatory agencies alike. By using techniques such as these, we can begin to level the playing field so that PK/PD measures for therapeutic agents can be more accurately compared with greater certainty, and not be limited to discussions of susceptibility method variation or comparisons of MIC results.
Collapse
|